Literature DB >> 3860186

Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.

J A Boscia, W D Kobasa, D Kaye.   

Abstract

This study compared enoxacin administered orally with cefoperazone administered intramuscularly for the treatment of Enterobacter aerogenes endocarditis in rabbits. The MICs and MBCs of both enoxacin and cefoperazone for an inoculum of 10(5) CFU/ml of the E. aerogenes strain used were 0.8 micrograms/ml, respectively. With an inoculum of 10(8) organisms per ml, enoxacin at 2 and 5 micrograms/ml and cefoperazone at 60 and 155 micrograms/ml were effective in reducing titers of E. aerogenes in broth. E. aerogenes endocarditis in rabbits was treated with enoxacin (100 or 25 mg/kg orally every 6 h) or cefoperazone (60 mg/kg intramuscularly every 6 h) for 5 or 10 days. Enoxacin at 100 and 25 mg/kg significantly reduced bacterial titers of vegetations compared with those of untreated controls. Enoxacin at 100 mg/kg was significantly more effective than enoxacin at 25 mg/kg and cefoperazone. Enoxacin at 25 mg/kg and cefoperazone did not differ significantly. Cefoperazone and controls did not differ significantly. In uninfected rabbits single doses of cefoperazone achieved much higher concentrations in serum than single doses of enoxacin (25 and 100 mg/kg). The half-lives of enoxacin at 25 and 100 mg/kg were approximately three times longer than that of cefoperazone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3860186      PMCID: PMC180137          DOI: 10.1128/AAC.27.5.708

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens.

Authors:  D T Durack; R G Petersdorf
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

2.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

4.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

5.  Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.

Authors:  W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

7.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

9.  Cefoperazone treatment of experimental endocarditis.

Authors:  R A Snepar; J Carrizosa; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

  9 in total
  6 in total

1.  In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Comparison of difloxacin, enoxacin, and cefoperazone for treatment of experimental Enterobacter aerogenes endocarditis.

Authors:  J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 5.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.